Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rifampicin strategies for HIV-associated tuberculous meningitis
ISRCTN42218549Phase 2Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifampicin in meningeal tuberculosis and human immunodeficiency virus infection (HIV) (3 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoints: Plasma and cerebrospinal fluid pharmacokinetics and Safety composite endpoint. Started Jun 2018; status: completed.
02
Drugs
rifampicin
03
Conditions
meningeal tuberculosishuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ISRCTN42218549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN42218549.